Background: The management of epilepsy incurs significant costs to the United Kingdom (UK) National Health Service (NHS). Making a diagnosis of epilepsy can, however, be difficult and misdiagnosis frequently occurs when patients are seen by non-specialists. This study estimates the financial costs of epilepsy misdiagnosis in the NHS in England and Wales. Methods: Standard costing methods were applied to estimate the costs attributable to epilepsy misdiagnosis. The primary data were published in UK studies on the prevalence of epilepsy, epilepsy misdiagnosis and costs identified from Medline, Cinahl and Embase (1996( -May 2006. Results: An estimated total of 92,000 people were misdiagnosed with epilepsy in England and Wales in 2002. The average medical cost per patient per year of misdiagnosis was £316, with the chief economic burdens being inpatient admissions (45%), inappropriate prescribing of antiepileptic drugs (AEDs) (26%), outpatient attendances (16%) and general practitioner (GP) care (8%). The estimated annual medical costs in England and Wales were £29,000,000, while total costs could reach up to £138,000,000 a year. Conclusions: Allowing for uncertainty, and considering the analysis exclusively from the NHS/CBS (community based services) perspective the opportunity costs of misdiagnosis are substantial. There is a need for health care commissioners to ensure that misdiagnosis is kept to a minimum by ensuring that individuals with a recent onset suspected seizure are seen as soon as possible by a specialist medical practitioner with training and expertise in epilepsy.
Introduction
The management of epilepsy incurs significant costs to the United Kingdom (UK) National Health Service (NHS). The medical cost to the NHS in 1992/1993 of newly diagnosed epilepsy in the first year of diagnosis was calculated as £18 million and the total annual cost of established epilepsy estimated at £2 billion, over 69% of which was due to unemployment and excess mortality (indirect costs). 1 The costs of treating epilepsy are likely to significantly increase given the new trends in prescribing patterns towards newer and more expensive antiepileptic drugs (AEDs). [2] [3] [4] A correct diagnosis of epilepsy requires that the clinician differentiate between seizures and other causes of transient neurological disturbance and collapse, such as syncope, and between acute symptomatic and unprovoked epileptic seizures. In an individual diagnosed with epilepsy, it is important that the correct classification of seizure type and epilepsy syndrome is made so that the individual with epilepsy can receive appropriate investigations, appropriate treatment, and information about the likely prognosis of the seizure type and/or syndrome. [5] [6] [7] 29 Making a diagnosis of epilepsy can be difficult. Misdiagnosis is a frequent occurrence, occurring in around 25% of cases. 8, 9 The majority of these occur when the diagnosis is made by a non-specialist. 9 Individuals misdiagnosed with epilepsy may experience social and financial deprivation as a result of having the wrong diagnostic label and from side-effects of antiepileptic medication. 10, 11 In addition, there may be a risk of unnecessary teratogenicity as a result of antiepileptic drug (AED) therapy in women incorrectly diagnosed as having epilepsy. In a small number of cases, individuals may die prematurely because the correct diagnosis was not made. 12 Individuals who have symptoms due to epileptic seizures but who are wrongly diagnosed as having psychiatric or associated disorders are disadvantaged by being labelled with an incorrect diagnosis and by the effects of continuing seizure activity because AEDs are not used.
In contrast to the documented physical and psychosocial effects of epilepsy misdiagnosis, little is known about the health economic costs of misdiagnosis in the United Kingdom (UK). The one published cost of illness study of epilepsy in the UK is now more than ten years old and focused on epilepsy in general, not the specific costs of misdiagnosis. 1 This study aimed to estimate the financial costs of epilepsy misdiagnosis in the NHS in England and Wales.
Methods
Standard costing methods 13 were applied to estimate the costs attributable to epilepsy misdiagnosis. The primary data were published UK studies on the prevalence of epilepsy, epilepsy misdiagnosis and costs identified from Medline, Cinahl and Embase (1966 ( -May 2006 . A systematic literature search was undertaken to identify these studies, the details of which are reported elsewhere. 7 The total number of misdiagnosed cases in epilepsy includes the number of true epilepsy cases diagnosed as other non-epileptic conditions plus the number of non-epileptic conditions diagnosed as epilepsy. The analysis focused only on estimating the costs of other conditions wrongly diagnosed as epilepsy (''false positives'') because this is the most common form of misdiagnosis and the majority of the published evidence addresses this type of misdiagnosis.
The perspective of the reference case is that of the National Health System (NHS) and Community Based Services (CBS).
a The complete financial burden of epilepsy misdiagnosis can, however, only be represented through a wider societal perspective, that includes, for example, the lost productivity due to morbidity or mortality for not treating the underlying condition and/or for being stigmatized as an individual with epilepsy (such as problems with employment or mobility problems due to driving restrictions).
The following steps were taken:
To estimate the number of misdiagnosed patients in England and Wales assuming prevalence and misdiagnosis rates based on published UK literature and applying these to the 2002 population of England and Wales. Only UK prevalence and misdiagnosis studies were included as it is important that these estimates can be generalised to the England and Wales population. In particular, variations in health care systems mean that misdiagnosis rates from non-UK settings are unlikely to be generalisable.
To estimate the annual average uses of resources and costs incurred by a misdiagnosed individual based on assumptions derived from published literature. All costs are estimated at 2003/4 prices adjusted for inflation by the hospital and community health and services (HCHS) pay and price index.
14 Table 1 Summary of published UK studies on epilepsy misdiagnosis
Evidence/author-studies Scheepers et al. 8 Smith et al. 9 Zaidi et al. 11 Leach et al. 21 Beach 
Results
Prevalence and misdiagnosis in the UKliterature review
Although epilepsy is the most common and one of the most serious neurological disorders worldwide, few studies that have examined its prevalence in the UK and these have examined relatively small populations. Also, most of these studies have used different methodologies and definitions and are based in different settings. From these studies, the prevalence of active epilepsy ranges between 4 and 10 cases per 1000. 2, [15] [16] [17] [18] [19] [20] This analysis used Purcell and colleague's prevalence of 7.7 cases of active epilepsy per 1000 to inform the reference case as this was a large recent population-based study conducted in England and Wales. To ensure that the findings took account of variations in prevalence we used two other UK population based studies to perform a sensitivity analysis on the main results.
Five primary papers were identified that assessed the frequency and causes of misdiagnosis in the UK. 8, 9, 11, 21, 22 (Table 1 ) There was heterogeneity among the studies as regard to population group selection and methods of analysis, with misdiagnosis rates ranging from 16% to 32% (Table 1 ). Scheepers' study was used to inform the reference case on the basis that it is the only population-based study that also reported the rate of misdiagnosis according to underlying condition. To ensure that the findings took account of variations in misdiagnosis rates we used the other published studies to perform a sensitivity analysis on the main results.
Considering a population of 52,000,000 in England and Wales (according to the 2002 census) and assuming an epilepsy prevalence of 7.7/1000 and a misdiagnosis rate of 23% an estimated total of 92,000 people were misdiagnosed with epilepsy in England and Wales in 2002.
Annual average use of resources and costs incurred by a misdiagnosed individual based on assumptions derived from published literature When possible a cost for the use of resources by misdiagnosed patients was used. However, only one paper was found to describe the use of medical resources by a group of misdiagnosed individuals because of their 'epilepsy' 8 and no study was found to describe the use of community social services resources by misdiagnosed patients. When data were unavailable average cost estimates reported in the literature for epilepsy patients were assumed. b
The average medical cost per patient per year of misdiagnosis was £316, with the chief economic burdens being inpatient admissions (45%), inappropriate prescribing of AEDs (26%), outpatient attendances (16%) and GP care (8%) ( Table 2 ). The estimated annual medical costs in England and Wales were £29,000,000 while total costs (including CBS costs c ) could reach up to £138,000,000 a year.
Sensitivity analysis
Changing the reference case and using the lowest prevalence data published in the UK for the general population of 4.3/1000 17 total cost estimates decrease to £76, 000,000 a year ( Table 2) . Instead if the highest prevalence data published for the UK of 9/1000 18 is used total costs could reach up to £161,000,000. If sensitivity analysis is performed on the reference case using a misdiagnosis rate of 16.3 21 the estimated total cost is £97,000,000. Combining prevalence and misdiagnosis rates that gives the lowest possible estimation for total costs (using misdiagnosis rate of 4.3/1000 and misdiagnosis rate of 16.3%) yields a total cost around £54, 000, 000.
The cost consequences of epilepsy misdiagnosis by true underlying condition
Cardiovascular and psychological conditions constitute the two groups systematically misdiagnosed as epilepsy. The number of misdiagnosed persons by real underlying condition was estimated. These rates were used to estimate national figures of misdiagnosed persons by the underlying condition and then costs (estimated on previous section) were assigned to these figures (Table 3 ). The two papers identified that assessed frequency, causes and consequences misdiagnosis were used to set lower and higher bounds on these estimations. The costs of epilepsy misdiagnosis in England and Wales 601 b Only two cost of illness studies were found for the UK. 8, 23 Based on date of publication Jacoby's paper was used for the reference case. d A third paper by Zaidi A. et al. 11 that reported misdiagnosis frequency by cause was identified. However, the focus of this study is on the identification of cardiovascular syncope in patients with apparent treatment-resistant epilepsy. Bold text highlights parameters of sensitivity analysis. a Distribution of medical costs as a percentage in parenthesis. b GP number of consultations were not reported so average costs 8 per patient on GP services were used. 23 Misdiagnosis of cases with a cardiovascular cause was estimated to lead to medical costs lying between £8,200,000 and £12,000,000 and community services related costs of £30,700,000 and £44,300,000. Misdiagnosis of cases with a psychological cause was estimated to lead to direct medical costs of £5,900,000 to £12,000,000 and community costs of £ 22,000,000 to £44,900,000. Total costs upper range estimation for cases with a cardiovascular cause was £56,200,000 and for cases with a psychological cause £56,900,000.
Discussion
This study has shown that the financial cost of epilepsy misdiagnosis to the NHS and community based services (CBS) in England and Wales is considerable. The estimated annual medical costs were £29,1000,000 while total costs could reach up to £137,800,000 a year with an average medical cost per patient per year of misdiagnosis was £316. The use of a sensitivity analysis, using lowest and highest reported prevalence and misdiagnosis rates, allows one to be reasonably certain that the ''true'' cost of misdiagnosis lies between £54,000,000 and £161,000,000. Thus, even allowing for uncertainty, epilepsy misdiagnosis leads to a high cost for the NHS and CBS in terms of the annual average use of wasted resources.
This study highlights the serious health consequences for the patients who are misdiagnosed and notes the high rates of potentially avoidable inpatient admissions, outpatient attendances and GP consultations and the inappropriate prescribing of AEDs.
It is important, however, to point out that the findings in this study have to be interpreted carefully as they have been obtained using published data on epilepsy prevalence and misdiagnosis rates. It is possible to be confident that the prevalence of epilepsy in England and Wales lies between 4.3 and 9 per 1000, as used in this study, as this is consistent with other published UK and international prevalence studies of active epilepsy (5-10 per 1000). 24 However, the data on misdiagnosis rates in the UK is limited 8, 9 and, owing to variations in health care systems, it is not possible to use non-UK data as a comparison. Furthermore, misdiagnosis rates are mainly based on studies focused on adult misdiagnosis. This is likely to mean that the magnitude of the problem could be higher for children given that the range of paroxysmal disorders occurring in children, which are often misdiagnosed as epileptic seizures, is far greater than that encountered in adults. 25 Other important costs and consequences of misdiagnosis which are not considered in this study due to lack of reliable data are: the cost of side effects caused by incorrect treatment and the forgone benefits in terms of health and quality of life when receiving the correct treatment. Also, if the perspective of the analysis was widen to include patient and societal costs it should have to consider the costs for the individuals and their families (for example, transport costs to the health centre hospital) and the costs of legal settlements for both misdiagnosed people and the NHS. In addition, cost estimates could further increase if one would also account for productivity loss due to unemployment and excess mortality. For example, in one study 9 23 out of 46 misdiagnosed persons were unemployed (or had lost or been refused a job), or were under threat of losing their job.
In conclusion, considering the analysis exclusively from the NHS/CBS perspective, we can say that the opportunity costs of misdiagnosis are substantial. This is especially true if it is considered that a large amount of resources currently 'lost' could be used to give the correct treatment to people misdiagnosed and to improve the quality of the treatment received by individuals with epilepsy. There is a need for health care commissioners to ensure that misdiagnosis is kept to a minimum by ensuring that recent national evidence-based clinical guidelines on the management of epilepsy are a General misdiagnosis rate assumed at 23%. b Assuming rates by misdiagnosed condition reported as 41% of total misdiagnosis for cardiovascular and cerebrovascular misdiagnosed condition and 20% for psychopathological conditions. 8 c Assuming rates by misdiagnosed condition reported as 28% of total misdiagnosis for cardiovascular misdiagnosed condition and 41% for psychopathological conditions. followed. 7, 26, 27, 29 Specifically, all individuals with a recent onset suspected seizure need to be seen as soon as possible by a specialist medical practitioner with training and expertise in epilepsy. If it is not possible to make a definite diagnosis of epilepsy after this assessment then further investigations and/or referral to a tertiary centre should be considered. 29 
